Thereafter, a phase III clinical trial with the selective estrogen receptor modulator (SERM), toremifene, in combination with ADT has shown a relative beneficial effect and a significant reduction of new vertebral fractures in patients with advanced PC [81,82,83]. This evidence concerns the gene ESR1 and pachyonychia congenita.